title: Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
abstract: Dramatically improved survival associated with tyrosine kinase inhibitor (TKI) therapy has transformed the disease model for chronic myeloid leukemia (CML) to one of long-term management, but treatment success is challenged with poor medication adherence. Many risk factors associated with poor adherence can be ameliorated by close monitoring, dose modification, and supportive care. Controlling risk factors for poor adherence in combination with patient education that includes direct communication between the health care team and the patient are essential components for maximizing the benefits of TKI therapy.
authors.affiliation: Department of Leukemia, Division of Cancer Medicine, The University of Texas: MD Anderson Cancer Center, Houston, USA. ejabbour@mdanderson.org
authors.forename: Elias J
authors.initials: EJ
authors.lastname: Jabbour
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Lina
authors.initials: L
authors.lastname: Eliasson
authors.forename: A Megan
authors.initials: AM
authors.lastname: Cornelison
authors.forename: David
authors.initials: D
authors.lastname: Marin
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D001549:Benzamides; D016527:Drug Costs; D016903:Drug Monitoring; D017048:Health Care Costs; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000191:economics; D055118:Medication Adherence; D010353:Patient Education as Topic; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases